MedTrace Logo

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

NCT03387904 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-09-02

No results posted yet for this study

Summary

To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).

Conditions

Interventions

DRUG

Anlotinib Plus Irinotecan

Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.

DRUG

Irinotecan

Irinotecan Day 1,8 ivgtt

Sponsors & Collaborators

  • The First Affiliated Hospital of Zhengzhou University

    lead OTHER

Principal Investigators

  • Feng Wang, doctor · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-13
Primary Completion
2021-12-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03387904 on ClinicalTrials.gov